Literature DB >> 1718615

Metabolism and alkylating activity of thio-TEPA in rat liver slice incubation.

B Hagen1, O Dale, G Neverdal, S Azri, O G Nilsen.   

Abstract

Precision-cut rat-liver slices were used to study the metabolism of the alkylating agent N,N',N''-triethylenethiophosphoramide (thio-TEPA). Exposure to high concentrations (1-10 mM) of thio-TEPA for 6 h did not prove to be toxic to the liver slices as indicated by insignificant leakage of potassium from the cells. The time course of the disappearance of thio-TEPA (initial concentration, 5.2 microM) from the buffer during incubation followed first-order kinetics. Formation of N,N'N''-triethylenephosphoramide (TEPA) apparently accounted for the elimination of thio-TEPA. Pretreatment of the rats with phenobarbital significantly increased the reaction rate. Conversely, pretreatment with the cytochrome P-450 inhibitor allylisopropylacetamide significantly reduced the metabolic rate. The elimination of thio-TEPA and formation of TEPA occurred independently of thio-TEPA concentration, which ranged from 5.2 to 104 microM. Thio-TEPA's oxo-analogue TEPA, which was not further metabolized, was the only metabolite identified. However, a significantly time-related increase in 4-(nitrobenzyl)-pyridine (NBP) alkylating activity was observed following incubation of liver slices with thio-TEPA but not after their incubation with TEPA. This may possibly indicate the formation of unknown active metabolites.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1718615     DOI: 10.1007/bf00685820

Source DB:  PubMed          Journal:  Cancer Chemother Pharmacol        ISSN: 0344-5704            Impact factor:   3.333


  22 in total

1.  Metabolic studies of 32P-labelled triethylenethiophosphoramide.

Authors:  A W CRAIG; B W FOX; H JACKSON
Journal:  Biochem Pharmacol       Date:  1959-12       Impact factor: 5.858

2.  Dose-dependent toxicity of CCl4 in isolated rat hepatocytes and the effects of hepatoprotective treatments.

Authors:  N Stacey; B G Priestly
Journal:  Toxicol Appl Pharmacol       Date:  1978-07       Impact factor: 4.219

3.  Rat liver slices: metabolic changes during short time incubation in glucose-free buffer.

Authors:  O Dale; T Holten; T Nørkov
Journal:  Pharmacol Toxicol       Date:  1990-07

4.  Human plasma pharmacokinetics and urinary excretion of thiotepa and its metabolites.

Authors:  B E Cohen; M J Egorin; E A Kohlhepp; J Aisner; P L Gutierrez
Journal:  Cancer Treat Rep       Date:  1986-07

5.  Gas chromatographic assay of triethylenethiophosphoramide in serum and urine.

Authors:  B Hagen; F Walseth; R A Walstad; T Iversen
Journal:  J Chromatogr       Date:  1985-11-29

6.  Differential haemin-mediated restoration of cytochrome P-450 N-demethylases after inactivation by allylisopropylacetamide.

Authors:  L M Bornheim; A N Kotake; M A Correia
Journal:  Biochem J       Date:  1985-04-01       Impact factor: 3.857

7.  Evidence for enzymatic activation and oxygen involvement in cytotoxicity and antitumor activity of N,N',N''-triethylenethiophosphoramide.

Authors:  B A Teicher; D J Waxman; S A Holden; Y Y Wang; L Clarke; E Alvarez Sotomayor; S M Jones; E Frei
Journal:  Cancer Res       Date:  1989-09-15       Impact factor: 12.701

8.  Effects of xylene and xylene isomers on cytochrome P-450 and in vitro enzymatic activities in rat liver, kidney and lung.

Authors:  R Toftgård; O G Nilsen
Journal:  Toxicology       Date:  1982       Impact factor: 4.221

9.  Plasma pharmacokinetics and tissue distribution of thiotepa in mice.

Authors:  M J Egorin; S R Akman; P L Gutierrez
Journal:  Cancer Treat Rep       Date:  1984-10

10.  Toxicity and biotransformation of volatile halogenated anesthetics in rat hepatocyte suspensions.

Authors:  A B DiRenzo; A J Gandolfi; S D Brooks; K Brendel
Journal:  Drug Chem Toxicol       Date:  1985       Impact factor: 3.356

View more
  1 in total

1.  Integrated Population Pharmacokinetic Model of both cyclophosphamide and thiotepa suggesting a mutual drug-drug interaction.

Authors:  Milly E de Jonge; Alwin D R Huitema; Sjoerd Rodenhuis; Jos H Beijnen
Journal:  J Pharmacokinet Pharmacodyn       Date:  2004-04       Impact factor: 2.745

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.